RT Journal Article
SR Electronic
T1 Seroprevalence of anti-SARS-CoV-2 IgG antibodies in hospitalized patients at a tertiary referral center in North India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.22.20179937
DO 10.1101/2020.08.22.20179937
A1 Ray, Animesh
A1 Singh, Komal
A1 Chattopadhyay, Souvick
A1 Mehdi, Farha
A1 Batra, Gaurav
A1 Gupta, Aakansha
A1 Agarwal, Ayush
A1 Bhavesh, M
A1 Sahni, Shubham
A1 Chaithra, R
A1 Agarwal, Shubham
A1 Nagpal, Chitrakshi
A1 Gagantej, B H
A1 Arora, Umang
A1 Sharma, Kartikeya Kumar
A1 Jadon, Ranveer Singh
A1 Upadhyay, Ashish Datt
A1 Nischal, Neeraj
A1 Vikram, Naval K
A1 Soneja, Manish
A1 Pandey, R M
A1 Wig, Naveet
YR 2020
UL http://medrxiv.org/content/early/2020/08/26/2020.08.22.20179937.abstract
AB Background Seroprevalence of IgG antibodies against SARS-CoV-2 is an important tool to estimate the true extent of infection in a population. However, seroprevalence studies have been scarce in South East Asia including India, which, as of now, carries the third largest burden of confirmed cases in the world. The present study aimed to estimate the seroprevalence of anti-SARS-CoV-2 IgG antibody among hospitalized patients at one of the largest government hospital in India.Method This cross-sectional study, conducted at a tertiary care hospital in North India, recruited consecutive patients who were negative for SARS-CoV-2 by RT-PCR or CB-NAAT. Anti-SARS-CoV-2 IgG antibody levels targeting recombinant spike receptor-binding domain (RBD) protein of SARS CoV-2 were estimated in serum sample by the ELISA method.Results A total of 212 hospitalized patients were recruited in the study with mean age (±SD) of 41.2 (±15.4) years and 55% male population. Positive serology against SARS CoV-2 was detected in 19.8% patients(95% CI 14.7-25.8). Residency in Delhi conferred a higher frequency of seropositivity 26.5% (95% CI 19.3-34.7) as compared to that of other states 8% (95% CI 3.0-16.4) with p value 0.001. No particular age groups or socio-economic strata showed a higher proportion of seropositivity.Conclusion Around, one-fifth of hospitalized patients, who were not diagnosed with COVID-19 before, demonstrated seropositivity against SARS-CoV-2. While there was no significant difference in the different age groups and socio-economic classes; residence in Delhi was associated with increased risk (relative risk of 3.62, 95% CI 1.59-8.21)Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by intramural funds of All India Institute Of Medical sciences, New Delhi. No external funding was received. Special acknowledgment to Translational Health Science And Technology Institute for processing SARS-CoV2 serum sample for antibody detectionAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:INSTITUTE ETHICS COMMITTEE FOR POST GRADUATE RESEARCH, ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHI, 110029,INDIAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be provided on request